Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 112, Issue SUPPL. 1, 2008, Pages 53-66

  Gligorov, Joseph ^a   Lotz, Jean Pierre ^a  

^a HÔPITAL TENON   (France)

Author keywords

Anthracyclines; Antiangiogenic; Bisphosphonates; Cardioprotectant; Chemotherapy; Endocrine therapy; Metastatic breast cancer; MTOR; Strategies; Taxanes

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HORMONE RECEPTOR; IBANDRONIC ACID; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; PAMIDRONIC ACID; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; TAXANE DERIVATIVE; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; HEART PROTECTION; HORMONE RESISTANCE; HUMAN; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; GENES, ERBB-2; HUMANS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 58249097457     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0232-x     Document Type: Article

References (95)

1. CT Chung RW Carlson 2003 Goals and objectives in the management of metastatic breast cancer Oncologist 8 514 520 10.1634/theoncologist.8-6-514
2. A Gennari P Conte R Rosso 2005 Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies Cancer 104 1742 1750 10.1002/cncr.21359
3. S Beslija J Bonneterre H Burstein 2007 Second consensus on medical treatment of metastatic breast cancer Ann Oncol 18 215 225 10.1093/annonc/mdl155
4. European School of Oncology (ESO)-MBC Task Force 2007 Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO). MBC Task Force Breast 16 9 10
5. VV Kataja M Colleoni J Bergh ESMO Guidelines Task Force 2005 ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC) Ann Oncol 16 Suppl 1 i10 i12 10.1093/annonc/mdi816
6. J Gligorov E Luporsi M Namer D Serin for the Saint Paul de Vence Guidelines Task force 2007 Breast cancer recommendations for clinical practice Oncologie 9 593 644 10.1007/s10269-007-0753-7
7. N Normanno M Di Maio E De Maio 2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr Relat Cancer 12 721 747 10.1677/erc.1.00857
8. S Carrick S Parker N Wilcken 2005 Single agent versus combination chemotherapy for metastatic breast cancer Cochrane Database Syst Rev 2 CD003372
9. BV Jensen 2006 Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer Semin Oncol 33 3 suppl 8 S15 S21 10.1053/j.seminoncol.2006.04.022
10. E Rivera 2003 Liposomal anthracyclines in metastatic breast cancer: clinical update Oncologist 8 Suppl 2 3 9 10.1634/theoncologist.8-suppl-2-3
11. RS Cvetkovic LJ Scott 2005 Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy Drugs 65 1005 1024 10.2165/00003495-200565070-00008
12. N Pavlakis R Schmidt M Stockler 2005 Bisphosphonates for breast cancer Cochrane Database Syst Rev 3 CD003474
13. J Bonneterre A Buzdar JM Nabholtz 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2247 2258 10.1002/1097-0142(20011101)92:9<2247::AID- CNCR1570>3.0.CO;2-Y
14. H Mouridsen M Gershanovich Y Sun 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2596 2606
15. R Paridaens P Therasse L Dirix 2004 First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)-a randomized phase III trial of the EORTC Breast Group J Clin Oncol 22 14S Abstract 515
16. AU Buzdar W Jonat A Howell 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer 83 1142 1152 10.1002/(SICI)1097- 0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7
17. P Dombernowsky I Smith G Falkson 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 453 461
18. M Kaufmann E Bajetta LY Dirix 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group J Clin Oncol 18 1399 1411
19. PE Lønning E Bajetta R Murray 2000 Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial J Clin Oncol 18 2234 2344
20. G Bertelli O Garrone M Merlano 2005 Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer Oncology 69 471 477 10.1159/000090985
21. N Steele J Zekri R Coleman 2006 Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure Breast 15 430 436 10.1016/j.breast.2005.08.032
22. P Carlini A Michelotti G Ferretti 2007 Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients Cancer Invest 25 102 105 10.1080/07357900701224789
23. YS Chin MJ Beresford D Ravichandran 2007 Exemestane after nonsteroidal aromatase inhibitors for post-menopausal women with advanced breast cancer Breast 16 436 439 10.1016/j.breast.2007.02.002
24. JF Robertson CK Osborne A Howell 2003 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials Cancer 98 229 238 10.1002/cncr.11468
25. S Chia W Gradishar 2008 Fulvestrant: expanding the endocrine treatment options for patients with hormone-receptor-positive advanced breast cancer Breast 17 Suppl 3 S16 S21 10.1016/j.breast.2007.12.004
26. T Safra J Greenberg IG Ron 2008 Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment? Isr Med Assoc J 10 339 343
27. Bartsch R, Mlineritsch B, Gnant M et al (2008) The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-008-0132-0
28. J Gligorov D Azria M Namer 2007 Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives Crit Rev Oncol Hematol 64 115 128 10.1016/j.critrevonc.2007.06.010
29. HA Lane D Lebwohl 2006 Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program Semin Oncol 33 2 suppl 7 S18 S25 10.1053/j.seminoncol.2006.03. 024
30. AE Wakeling 2005 Inhibitors of growth factor signalling Endocr Relat Cancer 12 Suppl 1 S183 S187 10.1677/erc.1.01014
31. G Demonty C Bernard-Marty F Puglisi 2007 Progress and new standards of care in the management of HER-2 positive breast cancer Eur J Cancer 43 497 509 10.1016/j.ejca.2006.10.020
32. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 10.1126/science.3798106
33. S De Placido C Carlomagno M De Laurentiis 1998 c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients Breast Cancer Res Treat 52 55 64 10.1023/A:1006159001039
34. JS Ross JA Fletcher 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Stem Cells 16 413 428
35. MJ Ellis A Coop B Singh 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808 3816
36. Kaufmann B, Makdey J, Clemens M et al (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). Ann Oncol 17(Suppl 9): Abstract LBA2
37. DS Salomon R Brandt F Ciardiello 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232 10.1016/1040-8428(94)00144-I
38. JM Knowlden IR Hutcheson HE Jones 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 1032 1044 10.1210/en.2002-220620
39. RI Nicholson IR Hutcheson ME Harper 2001 Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer Endocr Relat Cancer 8 175 182 10.1677/erc.0.0080175
40. I Chu K Blackwell S Chen 2005 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 18 25
41. SR Johnston 2005 Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations Clin Cancer Res 11 889s 899s
42. G Perez-Tenorio O Stal Southeast Sweden Breast Cancer Group 2002 Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients Br J Cancer 86 540 545 10.1038/sj.bjc.6600126
43. AS Clark K West S Streicher 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol Cancer Ther 1 707 717
44. K Yu L Toral-Barza C Discafani 2001 mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 249 258 10.1677/erc.0.0080249
45. LA de Graffenried WE Friedrichs DH Russell 2004 Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity Clin Cancer Res 10 8059 8067 10.1158/1078-0432.CCR-04-0035
46. NE Hynes A Boulay 2006 The mTOR pathway in breast cancer J Mammary Gland Biol Neoplasia 11 53 61 10.1007/s10911-006-9012-6
47. HA Sini C Wyder A Schnell 2005 The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade Clin Cancer Res 15 11 4521 4532 10.1158/1078-0432.CCR-04-1954
48. HA Lane C Schell A Theuer 2002 Antiangiogenic activity of RAD001, an orally active anticancer agent Proc Am Assoc Cancer Res 43 184 (Abstract 992)
49. A Boulay J Rudloff J Ye 2005 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 5319 5328 10.1158/1078-0432.CCR-04-2402
50. A O'Donnell S Faivre I Judson 2003 A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours Proc Am Soc Clin Oncol 22 200 (Abstract 803)
51. J Tabernero F Rojo H Burris 2005 A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors J Clin Oncol 23 193s 10.1200/JCO.2005.00.398 (Abstract 3007)
52. A Awada F Cardoso C Fontaine 2008 The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics Eur J Cancer 44 84 91 10.1016/j.ejca.2007.10.003
53. S Di Cosimo J Seoane M Guzman 2005 Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: a mechanistic based anti-tumor strategy J Clin Oncol 23 219s (Abstract 3112)
54. S Di Cosimo P Matar F Rojo 2004 The mTOR pathway inhibitor RAD001 induces activation of AKT which is completely abolished by gefitinib, an anti-EGFR tyrosine kinase inhibitor, and combined sequence specific treatment results in greater antitumor activity Proc Am Assoc Cancer Res 44 1233
55. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
56. R Fossati C Confalonieri V Torri 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31, 510 women J Clin Oncol 16 3439 3460
57. NJ Robert CL Vogel IC Henderson 2004 The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer Semin Oncol 31 Suppl 13 106 146 10.1053/j.seminoncol.2004.09.018
58. T Safra 2003 Cardiac safety of liposomal anthracyclines Oncologist 8 Suppl 2 17 24 10.1634/theoncologist.8-suppl-2-17
59. C Myers 1998 The role of iron in doxorubicin-induced cardiomyopathy Semin Oncol 25 10
60. R Ng N Better MD Green 2006 Anticancer agents and cardiotoxicity Semin Oncol 33 2 14 10.1053/j.seminoncol.2005.11.001
61. BB Hasinoff 1998 Chemistry of dexrazoxane and analogues Semin Oncol 25 4 suppl 10 3 9
62. F Villani M Galimberti E Monti 1990 Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat Toxicol Appl Pharmacol 102 292 299 10.1016/0041-008X(90)90028-S
63. JL Speyer MD Green A Zeleniuch-Jacquotte 1992 ICRF-187 permits longer treatment with doxorubicin in women with breast cancer J Clin Oncol 10 117 127
64. JL Speyer MD Green E Kramer 1988 Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer N Engl J Med 319 745 752
65. K Kolaric V Bradamante J Cervek 1995 A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide Oncology 52 251 255
66. M Venturini A Michelotti L Del Mastro 1996 Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer J Clin Oncol 14 3112 3120
67. JA Sparano J Speyer WJ Gradishar 1999 Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer J Clin Oncol 17 880 886
68. SM Swain FS Whaley MC Gerber 1997 Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 1318 1332
69. SM Swain FS Whaley MC Gerber 1997 Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy J Clin Oncol 15 1333 1340
70. L Seymour V Bramwell LA Moran 1999 Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group Cancer Prev Control 3 145 159
71. EC van Dalen HN Caron HO Dickinson 2005 Cardioprotective interventions for cancer patients receiving anthracyclines Cochrane Database Syst Rev 1 CD003917
72. D Ghersi N Wilcken J Simes 2005 Taxane containing regimens for metastatic breast cancer Cochrane Database Syst Rev 2 CD003366
73. WB Ershler 2006 Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer Oncologist 11 325 335 10.1634/theoncologist.11-4- 325
74. M Mano 2006 Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy Cancer Treat Rev 32 106 118 10.1016/j.ctrv.2005.12.008
75. IE Smith 2006 Overview of gemcitabine activity in advanced breast cancer Semin Oncol 33 3 suppl 9 S19 S23 10.1053/j.seminoncol.2006.03.020
76. KD Miller LI Chap FA Holmes 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 10.1200/JCO.2005.05.098
77. K Miller M Wang J Gralow 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113
78. Sledge G, Miller K, Moisa C et al (2007) Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 25(18S) (Abstract 1013)
79. Miles D, Chan A, Romieu G et al (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26 (Abstract LBA1011)
80. JJ Body 2006 Breast cancer: bisphosphonate therapy for metastatic bone disease Clin Cancer Res 12 6258s 6263s 10.1158/1078-0432.CCR-06-0840
81. D Santini ME Fratto B Vincenzi 2006 Zoledronic acid in the management of metastatic bone disease Expert Opin Biol Ther 6 1333 1348 10.1517/14712598.6.12. 1333
82. M Gnant B Mlineritsch G Luschin-Ebengreuth 2008 Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 840 849 10.1016/S1470-2045(08)70204-3
83. PF Conte LS Rosen D Gordon 2004 Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications Ann Oncol 15 Suppl 3 iii124 (Abstract 463PD)
84. Hei YJ, Saad F, Coleman RE, Chen YM (2005) Fractures negatively affect survival in patients with bone metastases from breast cancer. Breast Cancer Res Treat 88 (Abstract 6036)
85. GN Hortobagyi RL Theriault A Lipton 1998 Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16 2038 2044
86. RL Theriault A Lipton GN Hortobagyi 1999 Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group J Clin Oncol 17 846 854
87. N Kohno K Aogi H Minami 2005 Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J Clin Oncol 23 3314 3321 10.1200/JCO.2005.05.116
88. JT Sherer AT Adamus 2007 Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events Pharmacotherapy 27 207 217 10.1592/phco.27.2.207
89. DH Gordon 2005 Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials Clin Breast Cancer 6 125 131
90. A Wardley N Davidson P Barrett-Lee 2005 Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration Br J Cancer 92 1869 1876 10.1038/sj.bjc.6602551
91. R Wong PJ Wiffen 2002 Bisphosphonates for the relief of pain secondary to bone metastases Cochrane Database Syst Rev 2 CD002068
92. Hoff AO, Toth BB, Altundag K et al (2006) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 24 (Abstract 8528)
93. IJ Diel I Fogelman B Al-Nawas 2007 Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 64 198 207 10.1016/j.critrevonc.2007.07.005
94. RE Coleman P Major A Lipton 2005 Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 23 4925 4935 10.1200/JCO.2005.06.091
95. R Coleman J Brown E Terpos 2008 Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions Cancer Treat Rev 34 629 639 10.1016/j.ctrv.2008.05.001